cystic-fibrosis

Documents about cystic-fibrosis

• Personal narratives to support learning about lung transplant for people with cystic fibrosis.#421039NCBI PubMed Central
• Impact of Availability of Showerpatch for Patients With Intravenous Catheters#682978ClinicalTrials.gov
• Improving P. Aeruginosa Detection With Breath-based Diagnostics (IMPACT-Breath)#833493ClinicalTrials.gov
• Exercise in Child Health#845349ClinicalTrials.gov
• Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements#865984ClinicalTrials.gov
• Evaluation of Device Settings for Airway Clearance Using The Monarch Airway Clearance System#886560ClinicalTrials.gov
• Hypertonic Saline and Mucociliary Clearance in Children#901347ClinicalTrials.gov
• Aztreonam Lysine for Pseudomonas Infection Eradication Study#1009687ClinicalTrials.gov
• IPV vs CPT for Airway Clearance During CF Exacerbation#1045250ClinicalTrials.gov
• CFTR modulator response in nasal organoids derived from people with cystic fibrosis#288364IRIS
• Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis#903761ClinicalTrials.gov
• Evidence for altered immune-structural cell crosstalk in cystic fibrosis revealed by single cell transcriptomics#208761HAL (France)
• Tracking eco-evolutionary dynamics among lung pathobiome members from children with cystic fibrosis#273163Europe PMC
• Health State Utilities Associated With Treatment Burden in Cystic Fibrosis: A Patient Valuation Study.#427608NCBI PubMed Central
• Prediction of Antimicrobial Resistance in People Living With Cystic Fibrosis Using Machine Learning.#452873NCBI PubMed Central
• Data Management and Sharing Plan for: Research and Development Program Component II: Epithelial Function in Cystic Fibrosis#649090UNC Dataverse Dataverse OAI Archive
• Self-dispersing Liquids as Aerosol Drug Carriers#830906ClinicalTrials.gov
• EASY: Extended Access to Sollpura Over Years#839827ClinicalTrials.gov
• HERO-2: Home-Reported Outcomes With CFTR Modulator Therapy#851800ClinicalTrials.gov
• Multiple Breath Washout, a Clinimetric Dataset#872572ClinicalTrials.gov
• Qualitative Understanding of Experiences With the SIMPLIFY Trial#893912ClinicalTrials.gov
• Increase Tolerance for Exercise and Raise Activity Through Connectedness Trial#995407ClinicalTrials.gov
• Medication Adherence and Non-adherence in Adults With Rare Disease#909803ClinicalTrials.gov
• Using Health-related Quality of Life (HRQL) in Routine Clinical Care#902962ClinicalTrials.gov
• Relevance of 3D Cholangiography and Transient Elastography to Assess Cystic Fibrosis-Associated Liver Disease?#312095HAL (France)
• Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes?#342248IRIS
• A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists#800747ClinicalTrials.gov
• A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy#904286ClinicalTrials.gov
• Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis#1032854ClinicalTrials.gov
• International Delphi consensus recommendations for the follow-up of children born to people with CF and exposed to CFTR modulators in utero or through breastfeeding; endorsed by the European Cystic Fibrosis Society#157628HAL (France)
• RATNO, Reducing Antibiotic Tolerance Using Nitric Oxide in CF - a Phase 2 Pilot Study#141054ClinicalTrials.gov
• Base editing and nanoparticle transfection of airway cell types essential for treatment of cystic fibrosis.#258140NCBI PubMed Central
• Reporting of Telehealth Implementation in Cystic Fibrosis: Scoping Review Using a Novel Theory-Based Evaluation Lens.#266822NCBI PubMed Central
• Mucolytic Core-Shell Particles to Boost Levofloxacin Penetration Through the Mucus Barrier in Cystic Fibrosis.#285136NCBI PubMed Central
• Automated Airways Characterization and Assessment of Cystic Fibrosis from CT Imaging#377130bioRxiv / medRxiv
• Polymicrobial Extracellular Vesicles Reduce the Innate Immune Response of Human Cystic Fibrosis Bronchial Epithelial Cells.#427671NCBI PubMed Central
• MD2Me - Texting to Promote Chronic Disease Management#651213ClinicalTrials.gov
• Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)#855740ClinicalTrials.gov
• High Volumes of Hypertonic Saline and Chest Physiotherapy in CF Patients#886059ClinicalTrials.gov
• Lung Transplant READY CF 2: CARING CF Ancillary RCT#902437ClinicalTrials.gov
• A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor#911692ClinicalTrials.gov
• A rare case report of decompensated cirrhosis from hereditary hemochromatosis following lung transplant in a person with cystic fibrosis#684033eScholarship
• Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases#812299ClinicalTrials.gov
• Psychological impact of genetic eligibility for CFTR modulator therapy in children with cystic fibrosis and their parents.#25498NCBI PubMed Central
• Navigating Change – UK specialised adult cystic fibrosis service delivery in the highly effective modulator therapy era#120085Europe PMC
• Pharmacological inhibitors of the cystic fibrosis transmembrane conductance regulator exert off-target effects on epithelial cation channels#178298Ora Oxford University Research
• Use of Registry Data to Improve Center Outcomes and Inform Global Care Standards in Adult Cystic Fibrosis#234352bioRxiv / medRxiv
• Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®#279542ClinicalTrials.gov
• Open Label Extension to Bridging Study CTBM100C2303#832901ClinicalTrials.gov
• CPET in CF Patients With One G551D Mutation Taking VX770#854269ClinicalTrials.gov